Endocyte stock: buy or sell?
December 20th, 2018
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.
Should I buy Endocyte stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, 2 buy setups work for Endocyte stock now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Endocyte stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for ECYT stock for the last 30 days.
Endocyte stock analysis
After reaching all time highs , Endocyte remained stable -0.04% to $23.99.
Even closing lower ($23.99, -0.04%), Endocyte set new all time high at $24.00. ECYT shows a sign of strength in the short-term after finally breaking out above $23.94 and marking a new rising bottom. When ECYT stock price broke up the SMA100d line, it gained $8.43 (54.18%).
Endocyte inched 0.63% by mid December 2018 and set a new all time high at $24.00. With this, it's been 4 green weeks in a row, gaining $0.39 or 1.65%.
In a weekly time frame, Endocyte stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, ECYT might consolidate in a flat-base, waiting to break out over or down under . By mid October 2018 ECYT price bounced up over the SMA of 20 weeks that acted as support stopping new slides.
Endocyte stock price history
Endocyte stock went public on March 5th, 2018 with a price of $6.391. Since then, ECYT stock grew a 275.40%, with a yearly average of 275.40%. If you had invested $1,000 in Endocyte stock in 2018, it would worth $2,754.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Endocyte stock historical price chart
ECYT stock reached all-time highs with a price of $24.00.
Endocyte stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not found any price prediction for Endocyte stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, Endocyte reported its latest financial data, posting a decent growth for the Earnings per Share (EPS). Experts were expecting $-0.16 per share, but Endocyte posted $-0.17.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2017, Endocyte annual sales remained constant a tight 0.00% to $0.07 M USD from $0.07 marked in 2016. In contrary, its earnings margin (compared to sales) collapsed to -78,663.14%, that is $-55.06 million. Endocyte presents anual results in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Endocyte TTM sales up to September 2018 were $0.13 and income $-41.34 million USD. When comparing this TTM figures with the last reported annuality, we can esteem Endocyte business evolution since December 2017: Annual sales up to September, compared to lastest yearly report, boosted an exceptional 83.82%. Likewise, profit margin (net income/revenues) rocketed at -78,663.14%.
|2013||$65 M||-||$-18.03 M-27.8%||-|
|2014||$70 M||8.45%||$5.46 M7.8%||-130.28%|
|2015||$0.07 M||-99.90%||$-41.27 M-58956.7%||-855.93%|
|2016||$0.07 M||0.00%||$-43.89 M-62696.6%||6.34%|
|2017||$0.07 M||0.00%||$-55.06 M-78663.1%||25.47%|
|TTM||$0.13 M||83.82%||$-41.34 M-32126.5%||-24.93%|
Quarterly financial resultsEndocyte posted $0.09 million in revenues for 2018-Q3, a 493.54% up compared to previous quarter. Reported quarter earnings marked $-12.61 M with a profit margin of -14,684.64%. Profit margin boosted a 65,264.20% compared to previous quarter when profit margin was -79,948.84%. When comparing turnover to same quarter last year, Endocyte sales marked a super good increase and skyrocketed a 164.17%.
|2016-Q4||$0.01 M||-||$-11.07 M-92250.0%||-|
|2017-Q1||$0.01 M||4.17%||$-11.49 M-91920.0%||3.79%|
|2017-Q2||$0.01 M||0.00%||$-11.74 M-93920.0%||2.18%|
|2017-Q3||$0.03 M||160.00%||$-23.27 M-71590.2%||98.18%|
|2017-Q4||$0.01 M||-61.54%||$-8.56 M-68512.2%||-63.19%|
|2018-Q1||$0.02 M||26.84%||$-8.60 M-54258.3%||0.45%|
|2018-Q2||$0.01 M||-8.77%||$-11.56 M-79948.8%||34.43%|
|2018-Q3||$0.09 M||493.54%||$-12.61 M-14684.6%||9.02%|
Endocyte ownershipWhen you are planning to buy shares of a stock, it's worth to check its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Endocyte, of all outstanding shares are owned by its staff.
The following table compares ownership indicators for other stocks related to Endocyte:
|Market cap||$0.0 M|
|Total shares||0.0 M|
|Float shares||0.0 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Thursday, December 20th, 2018|
|Day range||$23.99 - $24.00|
|Average true range||$0.09|
|50d mov avg||$22.67|
|100d mov avg||$20.08|
|200d mov avg||$0.00|
Endocyte performanceTo measure stock performance is always good to compare with competitors or related stocks. We compared Endocyte against in the following table: